The rational management of fibromyalgia patients

Rheumatic Disease Clinics of North America

Volumn 28, Issue 2, 2002, Pages 181-199

  Bennett, Robert M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ALPRAZOLAM; AMITRIPTYLINE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; CARBIDOPA PLUS LEVODOPA; CLONAZEPAM; CYCLOBENZAPRINE; DEXTROMETHORPHAN; DOPAMINE RECEPTOR STIMULATING AGENT; DOXEPIN; GABAPENTIN; IMIPRAMINE; KETAMINE; METHADONE; MODAFINIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PERGOLIDE; SEROTONIN 1D ANTAGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TROPISETRON; UNINDEXED DRUG; ZOLPIDEM; ZOPICLONE;

BLADDER IRRITATION; CHRONIC FATIGUE SYNDROME; COGNITIVE DEFECT; DISTRESS SYNDROME; DOSE RESPONSE; DROWSINESS; DYSAUTONOMIA; EDUCATION; ENDOCRINE DISEASE; EVALUATION; EXERCISE; FIBROMYALGIA; HUMAN; IRRITABLE COLON; NOCICEPTION; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; REVIEW; SLEEP APNEA SYNDROME; SLEEP DISORDER; VERTIGO; WEIGHT GAIN; PSYCHOLOGICAL ASPECT;

FIBROMYALGIA; HUMAN; HUMANS;

EID: 0036302174     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(02)00002-9     Document Type: Review

References (111)

1. A database for fibromyalgia
2. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the Multicenter Criteria Committee
3. The concurrence of lupus and fibromyalgia: Implications for diagnosis and management
4. Determinants of WOMAC function, pain and stiffness scores: Evidence for the role of low back pain, symptom counts, fatigue and depression in osteoarthritis, rheumatoid arthritis and fibromyalgia
5. Fibrositis (Fibromyalgia) in rheumatoid arthritis
6. How important is patient education?
7. Education programmes for fibromyalgia patients: Description and evaluation
8. A randomized, controlled trial of exercise and education for individuals with fibromyalgia
9. Self-efficacy and outcome expectancies: Relationship to chronic pain coping strategies and adjustment
10. Pool exercise combined with an education program for patients with fibromyalgia syndrome. A prospective, randomized study
11. Effects of a three-year exercise program on motor function and cognitive processing speed in older women
12. Cognitive-educational treatment of fibromyalgia: A randomized clinical trial. I. Clinical effects
13. Emerging concepts in the neurobiology of chronic pain: Evidence of abnormal sensory processing in fibromyalgia
14. Connective tissue disease and other rheumatic conditions following breast implants in Denmark
15. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome
16. Is there muscle pathology in fibromyalgia syndrome?
17. The dorsal horn: State-dependent sensory processing, plasticity and the generation of pain
18. Dorsal horn neurophysiology of pain
19. Spinal cord pharmacology of pain
20. Pain mechanisms and management: A central perspective
21. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: New features for diagnosis
22. Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia
23. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome
24. Pharmacological treatment of fibromyalgia
25. Pain: Its physiology and rationale for management. Part I. Neuroanatomical substrate of pain
26. Neuroanatomy of the pain system and of the pathways that modulate pain
27. Anatomy and physiology of descending control of nociceptive responses of dorsal horn neurons: Comprehensive review
28. NK1 (substance P) receptor antagonists - Why are they not analgesic in humans?
29. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients
30. Pain analysis in patients with fibromyalgia: Effects of intravenous morphine, lidocaine and ketamine
31. Hyperexcitability in fibromyalgia
32. Dextromethorphan for the treatment of neuropathic pain: A double-blind randomised controlled crossover trial with integral n-of-1 design
33. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia
34. The N-methyl-D-aspartate receptor antagonist dextromethorphan selectively reduces temporal summation of second pain in man
35. Supplemental dextromethorphan in the treatment of fibromyalgia: A double-blind, placebo-controlled study of efficacy and side-effects
36. Effects of extraversion and neuroticism on experimental pain, clinical pain, and illness behavior
37. Sensory-affective relationships among different types of clinical and experimental pain
38. Pain affect encoded in human anterior cingulate but not somatosensory cortex
39. The role of psychological factors in chronic pain
40. "Unexplained" somatic symptoms, functional syndromes, and somatization: Do we need a paradigm shift?
41. Oral treatment of fibromyalgia with tropisetron given over 28 days: Influence on functional and vegetative symptoms, psychometric parameters and pain
42. Treatment of chronic fatigue syndrome with 5-HT3 receptor antagonists - Preliminary results
43. Alertness-enhancing drugs as a countermeasure to fatigue in irregular work hours
44. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy
45. Modafinil: The unique properties of a new stimulant
46. Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work. I. Effects on mood, fatigue, cognitive performance and body temperature
47. Clustering of sleep electroencephalographic patterns in patients with the fibromyalgia syndrome
48. Sleep and fibrositis syndrome
49. Induction of neurasthenic musculoskeletal pain syndrome by selective sleep stage deprivation
50. Sequential daily relations of sleep, pain intensity, and attention to pain among women with fibromyalgia
51. A review of the role of tricyclic medications in the treatment of fibromyalgia syndrome
52. A comparison of cyclobenzaprine and placebo in the management of fibrositis. A double-blind controlled study
53. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia
54. The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia
55. Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam: A double-blind, placebo-controlled study
56. The effect of zolpidem in patients with fibromyalgia: A dose ranging, double blind, placebo controlled, modified crossover study
57. Zopiclone in the treatment of sleep abnormalities in fibromyalgia
58. Effect of gamma-hydroxybutyrate on pain, fatigue, and the alpha sleep anomaly in patients with fibromyalgia. Preliminary report
59. The treatment of the restless leg syndrome with or without periodic leg movements in sleep
60. Randomized, double-blind, placebo-controlled trial of pergolide in restless legs syndrome
61. Treatment of periodic leg movement disorder and restless leg syndrome with talipexole
62. Restless legs syndrome improved by pramipexole: A double-blind randomized trial
63. The role of psychological factors in chronic pain. II. A critical appraisal
64. Relationship between the chronic pain grade and measures of physical, social and psychological well-being
65. Psychological symptoms and psychiatric diagnosis in patients with fibromyalgia
66. Comorbidity of fibromyalgia with medical and psychiatric disorders
67. Evaluation of the relationship between depression and fibromyalgia syndrome: Why aren't all patients depressed?
68. Antidepressant treatment of fibromyalgia. A meta-analysis and review
69. The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: Neuro-endocrine and target tissue-related causes
70. The neuroscience and endocrinology of fibromyalgia
71. A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis
72. Low levels of somatomedin C in patients with the fibromyalgia syndrome. A possible link between sleep and muscle pain
73. Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia
74. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia
75. Autonomic nervous system dysfunction may explain the multisystem features of fibromyalgia
76. Orthostatic sympathetic derangement in subjects with fibromyalgia
77. Dysautonomia among patients with fibromyalgia: A noninvasive assessment
78. Provocation of hypotension and pain during upright tilt table testing in adults with fibromyalgia
79. The connection between chronic fatigue syndrome and neurally mediated hypotension
80. The postural orthostatic tachycardia syndrome: A potentially treatable cause of chronic fatigue, exercise intolerance, and cognitive impairment in adolescents
81. Serotonin and central nervous system function
82. Perception of pain following aerobic exercise
83. Nociceptive threshold and physical activity
84. Beta-endorphin response to exercise. An update
85. Analgesia following exercise: A review
86. Changes in beta-endorphin levels in response to aerobic and anaerobic exercise
87. The contribution of muscle to the generation of fibromyalgia symptomatology
88. The fibromyalgia syndrome: Musculoskeletal pathophysiology
89. Immune activation: The role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states
90. Sleep and other symptoms in primary fibromyalgia and in healthy controls
91. Memory functioning in patients with primary fibromyalgia and major depression and healthy controls
92. Information processing in primary fibromyalgia, major depression and healthy controls
93. Cognitive dysfunction in fibromyalgia
94. Concentration and memory deficits in patients with fibromyalgia syndrome
95. Suffering: The contributions of persistent pain
96. High and low dose clonidine tests for the diagnosis of growth hormone deficiency
97. Bowel dysfunction and irritable bowel syndrome in fibromyalgia patients
98. Fibromyalgia in the irritable bowel syndrome: Studies of prevalence and clinical implications
99. Irritable bowel syndrome: New pharmaceutical approaches to treatment
100. Symptoms of Raynaud's syndrome in patients with fibromyalgia. A study utilizing the Nielsen test, digital photoplethysmography, and measurements of platelet alpha 2-adrenergic receptors
101. Comparison of patients with chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities
102. Chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities in a community-based sample of persons with chronic fatigue syndrome-like symptoms
103. Quality of life issues for fibromyalgia patients
104. Fibromyalgia and quality of life: A comparative analysis
105. Lack of correlation between the mean tender point score and self-reported pain in fibromyalgia
106. Group treatment of fibromyalgia: A 6 month outpatient program
107. Validity and reliability of the 6 minute walk in persons with fibromyalgia
108. The fibromyalgia impact questionnaire: Development and validation
109. A model to assess severity and impact of fibromyalgia
110. Treating fibromyalgia with a brief interdisciplinary program: Initial outcomes and predictors of response
111. Responsiveness of fibromyalgia clinical trial outcome measures